Table 2.
Clinicopathological and treatment variables in the patient population.
| All patients n = 149 (%) | |
|---|---|
| Clinical stage at diagnosis | |
| Resectable | 28 (18.8) |
| Borderline resectable | 31 (20.8) |
| Locally advanced | 30 (20.1) |
| Metastatic | 60 (40.3) |
| Histology | |
| Adenocarcinoma | 146 (98.0) |
| Squamous | 1 (0.7) |
| Adeno-squamous | 2 (1.3) |
| Differentiation | |
| Well differentiated | 2 (1.3) |
| Well-moderately differentiated | 4 (2.7) |
| Moderately to poorly differentiated | 26 (17.4) |
| Poorly differentiated | 30 (20.1) |
| Moderately differentiated | 50 (33.6) |
| HER2 overexpression | |
| Tested | 75 (50.3) |
| Positive | 16 (10.7) |
| Negative | 59 (39.6) |
| Not tested/unavailable | 74 (49.7) |
| MSI high/ MMR deficient tumor | |
| Yes | 0 |
| No | 96 (64.4) |
| Unavailable | 53 (35.6) |
| 1st line platinum chemotherapy | 82 (55) |
| Oxaliplatin | 80 (53.7) |
| Cisplatin | 2 (1.3) |
| Surgical treatment | 33 (22.1) |
| Neoadjuvant treatment | 22 (14.8) |
| Adjuvant treatment | 20 (13.4) |
| First-line treatment for inoperable disease | 114 (76.5) |
| FOLFIRNOX/mFOLFIRNOX | 49 (42.9) |
| Gemcitabine plus nab-paclitaxel | 41 (36) |
| Gemcitabine plus cisplatin | 2 (1.8) |
| Gemcitabine alone | 7 (6.0) |
| FOLFOX | 5 (4.4) |
| Capecitabine | 2 (1.8) |
| CAPIRINOX | 4 (3.5) |
| CAPOX | 2 (1.8) |
| Clinical trial | 2 (1.8) |
| Outcome of first-line treatment | |
| Progression, transition to 2nd line | 27 (18.1) |
| Intolerance, transition to 2nd line | 7 (4.7) |
| Ongoing treatment | 15 (10.1) |
| Progression, transition to supportive care | 16 (10.7) |
| Intolerance, transition to supportive care | 49 (32.9) |
| Targeted treatment | 3 (2.0) |
| Immunotherapy | 1 (0.7) |
| Radiation therapy to primary site | 31 (20.8) |